Artelo Biosciences Inc (NASDAQ:ARTL) saw its stock jump 10% after unveiling encouraging preclinical results for its lead drug ...

FABP5 captures endocannabinoids entering the neuron and delivers them to an enzyme that degrades them (station 1). Then, that degraded product is picked up by the same protein ...

FABP5 captures endocannabinoids entering the neuron and delivers them to an enzyme that degrades them (station 1). Then, that degraded product is picked up by the same protein ...

Detection of elevated FABP5 associated with additional tumor types suggests the target for ART26.12 may be more broadly relevant in cancer therapy Alderley Park Oncology Development Program is a ...

This protein helps to remove certain endogenous cannabinoids in the brain. By inhibiting FABP5, ART26.12 is able to increase the levels of these cannabinoids, like anandamide, ...

FABP5 is upregulated in numerous dermatological conditions, promoting inflammation and correlating with disease severity. Dr. Warren added, “Pre-clinical IND-enabling studies with ART26.12, ...

Fatty acid-binding protein 5 (FABP5) promotes lipolysis of lipid droplets, de novo fatty acid (FA) synthesis and activation of nuclear factor-kappa B (NF-κB) signaling in cancer cells.

High expression of FABP5 promotes fatty acid metabolism through lipolysis and de novo fatty acid synthesis in prostate and breast cancer cells. Activation of PKC and increase in ROS levels by ...

Artelo Biosciencs ARTL were up 46% on Aug 16, during market hours, after the company announced positive initial data from a pre-clinical study for one of its novel inhibitors to fatty acid binding ...

Artelo Biosciences Inc.’s IND application for ART-26.12, for the treatment of chemotherapy-induced peripheral neuropathy, has been granted clearance by the FDA allowing the company to initiate a first ...

Artelo Biosciences (ARTL) reports positive pre-clinical data from one of its FABP5 inhibitors in anxiety-related disorders. Stock up.

Artelo’s FABP5 inhibitor cleared to enter clinic for chemotherapy-induced peripheral neuropathy. July 16, 2024. Artelo Biosciences Inc.’s IND application for ART-26.12, for the treatment of ...